Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

RAPT Therapeutics Inc (RAPT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow RAPT Therapeutics's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
8.33 +0.21    +2.52%
03/05 - Closed. Currency in USD ( Disclaimer )
After Hours
8.44
+0.11
+1.32%
0:42:11 - Real-time Data
  • Volume: 422,978
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 8.15 - 8.58
Type:  Equity
Market:  United States
RAPT Therapeutics 8.33 +0.21 +2.52%

RAPT Therapeutics Company Profile

 
Read the RAPT Therapeutics Inc company profile to learn more about the business and the management team. View RAPT Therapeutics Inc facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

131

Equity Type

ORD

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company’s lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

Contact Information

Address 561 Eccles Avenue
South San Francisco, 94080
United States
Phone 650 489 9000
Fax -

Top Executives

Name Age Since Title
Brian Russell Wong 49 2015 CEO, President & Director
Linda Kozick 64 2016 Independent Director
William J. Rieflin 61 2015 Independent Chairman of the Board
Michael F. Giordano 63 2018 Independent Director
Alexander Rudensky - - Chairman of Scientific Advisory Board
David V. Goeddel 69 2015 Member of Scientific Advisory Board
Drew Mark Pardoll - 2017 Member of Scientific Advisory Board
Antoni Ribas 54 - Member of Scientific Advisory Board
Robert Zamboni - - Member of Scientific Advisory Board
Scott Joseph Antonia - 2017 Member of Scientific Advisory Board
Emma Guttman-Yassky - 2019 Member of Scientific Advisory Board
Philip D. Greenberg - 2017 Member of Scientific Advisory Board
Wendye Robbins 60 2019 Independent Director
Mary Ann Gray 69 2019 Independent Director
Lori M. Lyons-Williams 46 2021 Independent Director
Lawrence Fong - 2020 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

RAPT Price Commentary

Write your thoughts about RAPT Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email